ENTA (STOCKS)
Enanta Pharmaceuticals, Inc
$11.440000
-0.460000 (-3.87%)
Prev close: $11.900000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jay R. Luly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $334.11M
- Employees
- 131
- P/E (TTM)
- -4.41
- P/B (TTM)
- 2.97
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q2)
|
$-0.45 | $-0.50 | +0.0478 | +9.60% |
|
Dec 2025 (Q1)
|
$-0.42 | $-0.82 | +0.4037 | +49.01% |
|
Sep 2025 (Q4)
|
$-0.87 | $-1.04 | +0.1714 | +16.46% |
|
Jun 2025 (Q3)
|
$-0.85 | $-1.30 | +0.4520 | +34.72% |
Financial Statements
| Revenues | $69.21M |
| Benefits Costs and Expenses | $131.11M |
| Costs And Expenses | $129.60M |
| Nonoperating Income/Loss | -$1.51M |
| Operating Expenses | $129.60M |
| Depreciation and Amortization | $4.93M |
| Research and Development | $91.32M |
| Other Operating Expenses | $34.55M |
| Operating Income/Loss | -$60.38M |
| Income/Loss From Continuing Operations After Tax | -$61.98M |
| Income/Loss From Continuing Operations Before Tax | -$61.89M |
| Income Tax Expense/Benefit | $92.00K |
| Net Income/Loss | -$61.98M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$61.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$61.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.60 |
| Diluted Earnings Per Share | -$2.60 |
| Basic Average Shares | 36,514,336 |
| Diluted Average Shares | 36,514,336 |
| Assets | $314.70M |
| Current Assets | $178.41M |
| Noncurrent Assets | $136.29M |
| Fixed Assets | $33.11M |
| Other Non-current Assets | $103.18M |
| Liabilities | $198.12M |
| Current Liabilities | $46.44M |
| Accounts Payable | $4.36M |
| Wages | $2.94M |
| Other Current Liabilities | $39.14M |
| Noncurrent Liabilities | $151.68M |
| Equity | $116.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $116.59M |
| Liabilities And Equity | $314.70M |
| Net Cash Flow From Operating Activities | -$7.84M |
| Net Cash Flow From Operating Activities, Continuing | -$7.84M |
| Net Cash Flow From Investing Activities | -$59.54M |
| Net Cash Flow From Investing Activities, Continuing | -$59.54M |
| Net Cash Flow From Financing Activities | $42.10M |
| Net Cash Flow From Financing Activities, Continuing | $42.10M |
| Net Cash Flow | -$25.29M |
| Net Cash Flow, Continuing | -$25.29M |
| Comprehensive Income/Loss | -$61.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$62.49M |
| Other Comprehensive Income/Loss | $131.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$510.00K |